Ignite Creation Date:
2024-05-05 @ 5:23 PM
Last Modification Date:
2024-10-26 @ 9:31 AM
Study NCT ID:
NCT00447122
Status:
TERMINATED
Last Update Posted:
2022-03-08
First Post:
2007-03-12
Brief Title:
BrUOG-PA-209 Lapatinib and Gemcitabine for Metastatic Pancreaticobiliary Cancer
Sponsor:
Brown University
Organization:
Brown University
Study Overview
Official Title:
BrUOG-PA-209 Lapatinib and Gemcitabine for Metastatic Pancreaticobiliary Cancer A Phase I Study 108181
Status:
TERMINATED
Status Verified Date:
2022-01
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
slow enrollment and lack of funding
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Phase I study of lapatinib and gemcitabine for patients with metastatic pancreaticobiliary cancer
Detailed Description:
To evaluate the safetytolerability and potential antitumor activity of lapatinib at dose ranges of 1000 to 1500 mgd in combination with gemcitabine and gemcitabineoxaliplatin GEMOX in patients with advanced pancreaticobiliary cancer
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None